Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan 27;16(1):13-9.
doi: 10.1186/2047-783x-16-1-13.

Risk and fate of residual interatrial shunting after transcatheter closure of patent foramen ovale: a long term follow up study

Christoph Hammerstingl  1 , B Bauriedel, C Stüsser, D Momcilovic, I Tuleta, G Nickenig, D Skowasch
Affiliations

Risk and fate of residual interatrial shunting after transcatheter closure of patent foramen ovale: a long term follow up study

Christoph Hammerstingl et al. Eur J Med Res. .

Abstract

Background: Percutaneous transcatheter closure of patent foramen ovale (PFO) in cryptogenic stroke is an alternative to medical therapy. There is still debate on different outcome for each currently available device. The impact of residual shunting after PFO-closure on recurrent arterial embolism is unknown. -

Aims: (i) To evaluate the prevalence of residual interatrial shunting after device- closure of PFO, (ii) to identify risk factors predicting residual interatrial shunting after device implantation, and (iii) to investigate the outcome of patients after PFO-closure during long- term follow- up (FU).

Methods and results: Between 2000- 2005 PFO-closure was performed in 124 patients using four different devices: Amplatzer PFO-(n = 52), CardioSeal (n = 33), Helex (n = 23) and Premere (n = 16) occluder. All patients underwent serial contrast-enhanced transesophageal echocardiography (TEE) for 24 months after PFO- closure; clinical FU was at minimum 5 years up to 9.75 years (mean 6.67 ± 1.31 years). Overall-closure rate was 87% at 2 years, device-specific closure time curves differed significantly (p-logrank = 0.003). Independent risk factors for residual-shunting were implantation of a Helex occluder (hazard ratio [HR] 12.6, 95% confidence interval [CI] 2.6- 57.4, p = 0.002), PFO- canal- lengths (HR 1.2, 95%CI 1.1- 1.3, p = 0.004) and extend of atrial-septal-aneurysm (HR 1.1, 95%CI 0.9- 1.3; p = 0.05). 4 (3.2%) arterial embolic events occurred during a FU-period of 817.2 patient-years, actuarial annual thromboembolic-risk was 0.49%. All ischemic events were not related to residual PFO-shunting or device-related thrombus- formation.

Conclusion: Success rates of PFO- closure are mainly dependent on occluder-type, extend of concomitant atrial-septum-aneurysm and PFO-canal- length. Importantly, residual shunting after PFO-closure was not associated with recurrence of arterial embolism during long-term follow-up.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TEE results indicating device related closure rates during follow up.
Figure 2
Figure 2
TEE results indicating device related closure rates after 24 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Homma S, Di Tullio MR, Sacco RL, Mihalatos D, Li MG, Mohr JP. Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study. Stroke. 1994;25(3):582–586. doi: 10.1161/01.STR.25.3.582. - DOI - PubMed
    1. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112(7):1063–1072. doi: 10.1161/CIRCULATIONAHA.104.524371. - DOI - PubMed
    1. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M. et al.Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318(18):1148–1152. doi: 10.1056/NEJM198805053181802. - DOI - PubMed
    1. Windecker S, Meier B. Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale and cryptogenic stroke: to close or not to close? Closure: what else! Circulation. 2008;118(19):1989–1998. doi: 10.1161/CIRCULATIONAHA.107.757013. - DOI - PubMed
    1. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105(22):2625–2631. doi: 10.1161/01.CIR.0000017498.88393.44. - DOI - PubMed